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Abstract: The enzymes that regulate histone methylation states and the protein domains that recognize methylated histone 
residues have been implicated in a number of human diseases, including cancer, as a result of their ability to affect tran-
scriptional changes by altering chromatin structure. These proteins are recognized as potential therapeutic targets for the 
treatment of diseases associated with epigenetic disruption; however, few inhibitors of their activity have been identified. 
The majority of histone demethylase and methyltransferase enzyme inhibitors have been discovered on the basis of their 
structural similarity to substrates or known inhibitors of enzymes with analogous mechanisms. The general lack of po-
tency and specificity of these compounds indicates that novel chemotypes are needed to address the large number of re-
cently discovered histone-modifying enzymes. High-throughput screening (HTS) allows rapid testing of chemically di-
verse small molecule libraries, provided assays amenable to HTS exist. Here we review the biochemical and cellular as-
says available for testing the proteins and enzymes that regulate histone methylation. Progress in the development of high-
throughput, sensitive, and robust assays will enable discovery of small molecules for epigenetic therapy. 
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INTRODUCTION 
  Post-translational modifications (PTMs) of histones, in-
cluding acetylation, methylation, ubiquitination, and phos-
phorylation, affect the transcription of associated genes by 
altering local chromatin structure and the accessibility of 
transcription factors [1]. These epigenetic marks also act as 
beacons in the recruitment of enzymes that further modify 
the landscape of histone PTMs or DNA methylation, or that 
directly (de)stabilize chromatin structure [2]. Both the en-
zymes that regulate the addition or removal of histone modi-
fications and the proteins harboring domains that recognize 
specific PTMs have been implicated in a variety of human 
diseases, including cancer. 
  The most thoroughly characterized histone modification 
is lysine acetylation which generally leads to an increase in 
transcriptional activity following the loss of lysine’s positive 
charge with acetylation and decreased electrostatic interac-
tion with the negatively-charged DNA backbone [3]. Histone 
deacetylase (HDAC) inhibitors have been used in the clinic 
to promote hyperacetylation of histone tails and reactivate 
aberrantly silenced tumor suppressor genes [4]. The func-
tional consequence of histone methylation is more complex, 
with methylation of both arginine and lysine possible, and 
transcriptional changes dependent on the site and degree of 
methylation. For example, methylation at H3K9, H3K27,   
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and H4K20 typically leads to repressed transcription, 
whereas methylation at H3K4 and H3K36 results in en-
hanced transcriptional activation [5].  
  Research on the mechanisms and regulation of histone 
methylation has intensified in the last decade in response to 
the discovery that histone methylation is impermanent and 
the identification of histone demethylases. This surge of ac-
tivity surrounding epigenetics has resulted in the discovery 
of greater than 50 methyltransferase enzymes, 30 histone 
demethylases, and numerous protein domains that recognize 
and bind methylated histone residues. To study these PTMs 
and the mechanisms of enzymes that regulate them has ne-
cessitated the development of various biochemical and cell-
based assays. In addition, validating the involvement of 
many of these proteins in human disease has generated con-
siderable interest in the discovery of small molecule inhibi-
tors of histone-modifying enzymes and of compounds that 
disrupt the interactions between histones and the domains 
that bind specific PTMs, the so-called “readers” of the his-
tone code.  
  Here we review recent advances in methods to study his-
tone methylation with a focus on the discovery of small 
molecule modulators of histone methyltransferases, demeth-
ylases, and reader domains as potential therapeutic agents in 
the treatment of cancer and other diseases associated with 
epigenetic deregulation. To date, no fewer than six high-
throughput screens of epigenetic targets have been per-
formed with more than 200,000 compounds and published 
on the open-access PubChem database (http://pubchem.ncbi. 
nlm.nih.gov/), demonstrating the need for robust high-
throughput assays and techniques for rapid characterization 
of the downstream effects of compounds that influence his-96    Current Chemical Genomics, 2011, Volume 5  Quinn and Simeonov 
tone PTMs. While acknowledging the importance of histone 
acetylation, phosphorylation, and other PTMs in the devel-
opment of a spectrum of human diseases, we direct our at-
tention here to the rapidly-evolving field of histone methyla-
tion. 
METHYLTRANSFERASE ASSAYS 
Radiotracer Assays 
  Radioactivity-based assays to measure histone methyl-
transferase activity are sensitive, easy to configure, and ap-
plicable to a diverse range of enzymes. Filter binding assays 
measure transfer of tritiated methyl groups from [
3H]-SAM 
to a substrate, followed by removal of unreacted [
3H]-SAM 
and retention of radiolabeled-product by filtration and sub-
sequent scintillation counting (Fig. 1A). The fungal myco-
toxin metabolite chaetocin (3,6-epi-dithio-diketopiperazine) 
was one of the first methyltransferase inhibitors discovered 
by screening 3,000 compounds against the Drosophila 
melongaster SU(VAR)3-9 lysine methyltransferase using a 
radioactive histone H3 peptide filter binding assay (Table 1) 
[6]. Filters assembled in 96- and 384-well vacuum plates 
have increased the throughput of this assay. Other plate-
based techniques include immobilization of a biotinylated 
peptide substrate in an avidin/streptavidin-plate and removal 
of free [
3H]-SAM with washing steps. The washing steps 
Table 1.  Methods Used in the Discovery of Small Molecule Inhibitors of Histone Methyltransferase and Demethylase Enzymes 
Method Compound  Target  Secondary  Assays 
Radiotracer Assays 
Chaetocin [6]  SU(VAR)3-9  Biochemical and cellular immunoblot, MS  Filter Binding 
Pyrazole Amide 7b [68]  PRMT4  PRMT1, PRMT3 selectivity (filter binding) 
[
14C]-Labeling  Sinefungin [69]  N.D.  N.D. 
Antibody-Based Assays 
DELFIA  BIX-01294, BIX-01338 [13, 32]  G9a, GLP  MS, Cellular expression analysis, ChIP 
ELISA  AMI-1, AMI-5 [12]  Hmt1p, PRMT1  Filter binding, ER-reporter gene assay 
Coupled Enzyme Assays 
Myricetin, -lapachone [45] JMJD2E  MS  FDH-Coupled 
8-hydroxyquinolines [43]  JMJD2E, 2A  MS, FRAP 
Mass Spectrometry (MS) 
  Disulfiram or selenium derivatives [70]  JMJD2A  Zn(II)-ejection assay 
Fluorescence Polarization (FP) 
  Stilbamidine, allantodapsone, RM-65 [14, 71]  RmtA, PRMT1  TRF, ER -reporter gene assay, cellular IHC 
Crystallography/Modeling/Virtual Screening 
UNC-0321 [17]  G9a, GLP  SAHH-coupled assay, AlphaScreen, FP, MCE 
E70 [72]  GLP  MS, ITC, cellular expression analysis 
Tranylcypromine-Lys conjugates [73]  LSD1  HRP-coupled assay, cellular immunoblot 
2,4-PDCA [33]  JMJD2E, 2A  FDH-coupled assay, MS, crystallography 
4-dimethyl-amino-benzyl-NOG [74]  JMJD2A, 2C, 2D  Biochemical and cellular immunoblot 
 
N-oxalyl-D-tyrosine derivatives [75]  JMJD2A  MS, FDH-coupled assay, crystallography 
Structural or Mechanistic Similarity 
Tranylcypromine [48]  LSD1  Immunoblot, ChIP, transcriptional analysis 
Lys4-cyclopropyl and propargylamine H3 pep-
tide derivatives [50] 
LSD1  HRP-coupled assay, MS 
Bisguanidine and biguanide polyamine analogs 
[54] 
LSD1  Biochemical and cellular immunoblot, transcriptional analy-
sis, ChIP 
N-oxalylglycine (NOG) [76]  JMJD2E, 2A, 2B  Immunoblot, FDH-coupled assay 
 
Succinic acid [77]  JMJD2D  Biochemical and cellular immunoblot 
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may be eliminated with the use of avidin/streptavidin-coated 
FlashPlates that contain a thin layer of scintillant bound to 
the walls of the microplate wells where the signal is based on 
isotope proximity [7].  
  Transfer of tritiated methyl groups from [
3H]-SAM to a 
bead-bound substrate provides a homogeneous, sensitive 
method for rapidly measuring methyltransferase activity 
(Fig. 1B). Scintillation proximity assays (SPA) utilize micro-
scopic beads containing scintillant. The interaction of these 
beads with -particles generated by the radioactive decay of 
tritium releases photons that may be measured with scintilla-
tion counters or charge-coupled device (CCD) imagers. A 
variety of SPA bead formats allows utilization of various 
methyltransferase substrates, from biotinylated histone pep-
tides to nucleosomes. The lack of a separation step and in-
trinsic sensitivity of the assay make SPA techniques amena-
ble for HTS. However, the use of radioactivity is undesirable 
due to health risks as well as the cost of radiolabeled sub-
strate and waste disposal. Thus the development and use of 
non-radioactive assays should be utilized whenever possible. 
Coupled Enzyme Assays 
  Simple substrate-to-product conversion is difficult to 
monitor in histone methyltransferase reactions where the 
spectral differences in SAM and SAH are insufficient for 
direct monitoring. Several coupled assays have been used to 
measure the SAH product of methyltransferases (Fig. 1C). 
The cysteine-free SAH hydrolase of Sulfolobus solfataricus 
generates a free thiol in homocysteine that may be measured 
with thiol-sensitive fluorophores [8], including the malei-
mide derivatives ThioGlo 1 [methyl-10-(2,5-dioxo-2,5-dihydro-
1H-pyrrol-1-yl)-9-methoxy-3-oxo-3H-benzo[f]chromene-2-
carboxylate] and CPM (7-diethylamino-3-(4’-maleimidyl-
phenyl)-4-methylcoumarin) [8, 9]. The free thiol of homo-
cysteine may also be measured by reaction with DTNB 
(5,5’-dithiobis-2-nitrobenzoic acid) to form the colored 
product TNB (5-thio-2-nitrobenzoic acid). Homocysteine 
may also be generated from SAH through the consecutive 
actions of SAH nucleosidase (SAHN) to generate adenine 
and  S-ribosylhomocysteine and LuxS (S-ribosyl-
homocysteinase) to cleave the latter intermediate to form 
Hcy [10]. Alternatively, the adenine product of SAHN may 
be utilized by adenine deaminase to form hypoxanthine, 
where a decrease in UV-absorbance is monitored at 265 nm 
[11]. The SAHH/ThioGlo assay described by Collazo et al. 
[8] is likely the most straightforward and sensitive of these 
methods to measure SAH production, considering the single 
coupling enzyme and fluorescence detection. However, as-
say components must be carefully selected to minimize 
background fluorescence due to the reaction of free thiols 
with ThioGlo 1, and chemical blocking of free thiols of the 
substrate or enzyme may be considered. Coupled enzyme 
assays are inherently more difficult to optimize and suscepti-
ble to false positives when seeking enzyme inhibitors. None-
theless, the removal of SAH in the coupling assays described 
here is advantageous for relief of SAH product inhibition, a 
characteristic common to histone methyltransferases. 
Antibody-Based Techniques 
  Several biochemical assays have been developed that rely 
on antibody recognition of specific post-translational modifi-
cations. Enzyme-linked immunosorbent assays (ELISA) for 
histone methyltransferases involve immobilization of bi-
otinylated histone peptide substrate on an avidin-coated mi-
croplate. Following enzymatic methylation of Lys or Arg 
residues on the immobilized peptide, a primary antibody 
specific to the PTM is captured on the plate. A secondary 
antibody conjugated with horseradish peroxidase (HRP) is 
used for chemiluminescence detection. The first protein ar-
ginine methyltransferase (PRMT)  inhibitor AMI-1, a sym-
metrical sulfonated urea, was identified in an ELISA-based 
HTS assay of 9,000 diverse compounds using fungal Hmt1p 
(also known as Rmt1p) and the hnRNP protein Npl3p (Table 
1) [12]. AMI-1 is a non-specific arginine methyltransferase 
inhibitor, although it does not affect methylation of lysine.  
  A modern version of the ELISA is the dissociation-
enhanced lanthanide fluorescent immunoassay (DELFIA) 
where the secondary antibody is labeled with a lanthanide 
chelate (typically europium) instead of HRP, and product 
formation is measured with time-resolved fluorescence 
(TRF). This technique was used to identify the first inhibitor 
of a histone lysine methyltransferase that was not competi-
tive with the SAM cosubstrate. BIX-01294 was discovered 
in a screen of 125,000 compounds as a selective inhibitor of 
the G9a lysine methyltransferase (IC50 2.7 μM) and was 
competitive with the histone H3 peptide substrate (Table 1) 
[13]. BIX-01338 was also identified in this screen as a G9a 
inhibitor (IC50 4.7 μM), but it also inhibited other Lys and 
Arg methyltransferases and was SAM-competitive. Inhibi-
tors of the arginine methyltransferase PRMT1 were also 
identified using a DELFIA assay to screen compounds se-
lected by iterative virtual screening of the National Cancer 
Institute (NCI) diversity collection [14]. Two of the com-
pounds active in the PRMT1 in vitro assay, allantodapsone 
and stilbamidine, were validated by demonstrating hy-
pomethylation of H4R3 in HepG2 cells and inhibition of 
ER-transcriptional activation in a cell-based reporter assay.  
  Antibody detection has also been used in a homogeneous 
assay utilizing AlphaScreen technology to measure histone 
G9a methyltransferase activity [15]. This dual bead-based 
technology utilizes laser excitation of donor beads, releasing 
a flow of singlet oxygen to generate chemiluminescent emis-
sion from acceptor beads in close proximity (Fig. 1D). Ac-
ceptor beads coated with secondary antibody are coupled to 
specific antibody detection of enzyme-modified substrates. 
AlphaScreen was used in the structural optimization of the 
BIX-01294 inhibitor of G9a, and IC50 values obtained 
tracked closely with those measured in a SAHH/ThioGlo 1 
coupled assay [16, 17]. These studies led to the discovery of 
UNC0224 and UNC0321, the most potent G9a inhibitors 
identified to date (Table 1). The advantage of this assay 
compared to ELISA-based methods is the homogeneous na-
ture of AlphaScreen where elimination of washing and sub-
strate immobilization steps leads to an increased assay 
throughput. Importantly, the AlphaScreen assay was readily 
miniaturized to 1,536-well plate format allowing for its use 
in screening large compound collections [15]. 
  AlphaScreen assays to measure histone methyltransferase 
activity may utilize direct coupling of the acceptor bead to 
the primary antibody in place of a secondary anti-
immunoglobulin donor bead plus primary antibody. Some 
methyl mark antibodies directly conjugated to acceptor 98    Current Chemical Genomics, 2011, Volume 5  Quinn and Simeonov 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Histone methyltransferases assay formats. Filter binding assays to measure histone methyltransferase activity utilize radiolabeled 
SAM to measure transfer of tritiated methyl groups to histone substrates (A). Unreacted 
3H-SAM is removed from reaction solutions via fil-
tration through a vacuum plate. Addition of scintillation fluid permits quantitation of radiolabeled products retained on the filter plate. (B) 
SPA methyltransferases assays utilize beads containing scintillation fluid that emit light when excited by -particles released from radioactive 
decay of bead-bound substrates. (C) Coupled enzyme assays measure histone methyltransferase activity by transformation of SAH to prod-
ucts that can be measured by fluorescence or UV/Vis spectroscopy via Hcy or S-ribosyl-homocysteine intermediates. (D) Methylation of a 
biotinylated histone peptide by AlphaScreen is measured using streptavidin-coated donor beads and anti-immunoglobulin–conjugated accep-
tor beads in the presence of a specific antibody raised against the methylated lysine product. Transfer of singlet oxygen from laser-excited 
donor beads to acceptor beads in close proximity results in a chemiluminescent signal. (E) The LysC endoproteinase distinguishes between 
methyltransferase substrate and product peptides by selective proteolysis at unmodified lysine residues. Electrophoretic separation of tagged 
fluorescent peptides permits quantitation of enzymatic activity following proteolysis with LysC. 
beads are commercially available (http://las.perkinelmer. 
com/).  In vitro AlphaScreen assays most commonly use 
streptavidin-coated donor beads to bind biotinylated peptide 
substrates. However, donor beads may be conjugated with 
antibodies that recognize histone substrates at a site distinct 
from that modified by the methyltransferase or demethylase 
enzyme. This sandwich-based approach is suitable for en-
zymes with no or low activity towards peptide substrates as 
well as for cell-based quantitation of histone-modifying en-
zyme activity. 
  Time-resolved fluorescence resonance energy transfer 
(TR-FRET), like AlphaScreen, is a proximity based tech-
nique that may be used to measure enzymatic activity of his-
tone-modifying enzymes. TR-FRET combines time-resolved 
fluorescence (TRF) and FRET in a homogeneous format 
where fluorescence emission of a donor dye overlaps with 
the excitation spectrum of an acceptor dye. Whereas Al-
phaScreen donor and acceptor molecules may be separated 
by up to 200 nm, the distance of interaction is typically lim-
ited to 1-10 nm for TR-FRET. To date, FRET has only been 
used to measure inhibition of HDAC activity in cells using a 
baculovirus-expressed GFP-p53 fusion protein [18]. A ter-
bium-labeled acetyl-p53 (Lys382) antibody was used to 
measure activity of the p300 histone acetyltransferase (HAT) 
using the non-histone GFP-p53 substrate where GFP is the 
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FRET acceptor. We note that if an endpoint assay based on 
antibody detection is desired, the traditional method of stop-
ping the enzymatic reaction by addition of acid will not be 
usable: instead, an addition of EDTA at a millimolar concen-
tration can be used as an alternative.  
  The limitations of these techniques lie in the availability 
of specific antibodies, particularly in assays that require dis-
crimination between mono- and dimethylated or di- and tri-
methylated residues [19]. Examination of more than 200 
antibodies raised against 57 different histone modifications 
found that 25% of these failed specificity testing by Western 
blot and dot blot analysis, and 20% of the specific antibodies 
were deemed unsuitable for chromatin immunoprecipitation 
(ChIP) analysis [20]. The high failure rate prompted the 
authors to create a website for posting these and new results 
of antibody specificity tests for the detection of epigenetic 
marks (http://compbio.med.harvard.edu/antibodies/). Where 
specific antibodies are not available, the use of tagged chro-
matin binding domains to measure changes in levels of spe-
cific post-translationally modified residues has been sug-
gested (Wigle, T.J., personal communication), although it is 
unclear whether the micromolar affinities typical of reader 
domains for their cognate epigenetic mark would be suffi-
cient for such applications. Additional complications in at-
tempting to quantify PTMs with reader domains in a cellular 
environment may result from the observation by Fuchs et al. 
that neighboring PTMs can affect the affinity of chromatin-
associated domains for a particular epigenetic mark [21]. 
Using a library of histone peptides with single or multiple 
PTMs immobilized in a peptide array, both enhanced and 
diminished binding of several reader domains were observed 
for combinations of PTMs. Using the same peptide array, the 
authors also found the specificity of some commercial anti-
bodies raised against a specific epigenetic mark were af-
fected by other PTMs present on the peptide bait [21].  
Capillary Electrophoresis 
  The principles of capillary electrophoresis applied to a 
microfluidic chip (MCE) allow separation of nanoliter-sized 
samples based on the charge-to-mass ratio of the components 
of interest. The loss of lysine’s positive charge with acetyla-
tion results in facile electrophoretic separation of substrate 
and product peptides and offers a direct method for measur-
ing HAT or HDAC activity. This type of electrophoretic 
mobility shift assay has been used to profile inhibitors of 
HDAC and HAT enzymes, including PCAF and GCN5L2 
[22, 23]. A similar approach may be employed for changes 
in phosphorylation of histone peptides. 
  Methylation of lysine, however, does not change the 
positive charge of this amino acid, rendering a direct electro-
phoretic separation impossible. To address this limitation, 
methods originally developed for methyllysine mapping of 
histones by mass spectrometry (MS) have recently been ap-
plied to MCE. These techniques use the endoproteinase 
LysC to selectively cleave at the carboxyl side of unmodified 
lysine residues, leaving methylated lysine polypeptides intact 
(Fig. 1E). Such a histone mark-dependent cleavage allows 
for the production of fluorescent peptides of different 
charge-to-mass ratios. The utility of this method was demon-
strated using LysC and fluorescent-labeled histone peptides 
for inhibitor screening and mechanism of action studies of 
the G9a methyltransferase and the LSD1 lysine demethylase 
[24]. The G9a MCE assay was used to determine the Morri-
son  Ki (63 pM) of UNC0321, the 2,4-diamino-7-
aminoalkoxy-quinazoline compound designed from the BIX-
01294 chemical scaffold (Table 1) [17]. The multiplicity of 
Lys residues in the N-terminal tails of histones, however, 
complicates generation of suitable peptides upon LysC 
cleavage and may require mutation or chemical modification 
of non-substrate Lys residues in substrate peptides. In addi-
tion to measuring lysine methyltransferase activity, protease-
coupled MCE may be applicable to monitoring Arg methyla-
tion with the use of the ArgC endoproteinase [24]. 
Mass Spectrometry 
  Mass spectrometry (MS) has been an important tool in 
identifying novel PTMs as well as characterizing activities of 
histone-modifying enzymes [25]. The majority of this work 
has been performed using a bottom-up approach where pro-
teins are digested into small peptides prior to MS analysis. 
Tandem mass spectrometry (MS/MS) is used to map the site 
of modification and reconstruct protein identity using se-
quence information. The major disadvantage to this approach 
is that information on the combinatorial nature of histone 
modifications is lost. A top-down approach, on the other 
hand, refers to MS analysis of intact proteins to yield infor-
mation on combinations of modifications and their relative 
abundance [26]. This is particularly useful in the analysis of 
heterogeneous mixtures of histones, for example in tissues 
and cell culture.  
  An intermediate approach to these techniques was con-
structed to mitigate the need for a high-resolution mass ana-
lyzer in top-down MS while retaining information on the 
interplay between PTMs on a single histone polypeptide. In 
middle-down MS, limited proteolysis of histones with endo-
proteinases such as GluC or AspN generates polypeptides of 
up to 50 residues [27]. As the majority of PTMs are located 
on the N-terminal tails of these proteins, information on the 
complex spectrum of histone PTMs is gained with middle-
down MS. This MS proteomics method has been used for 
global assessment of combinatorial PTMs and their tissue-
specific abundance [28].  
  Quantitative MS has been used to measure enzymatic 
activity of histone-modifying enzymes. In vitro approaches 
generally target specific PTMs and use MS peak intensities 
of high resolution, well-defined peptides for relative quanti-
tation of product formation (Fig. 2A). This label-free method 
has been used to measure activities of numerous histone-
modifying enzymes [29-31] and to determine inhibitor po-
tency [32, 33]. An internal standard for normalization that 
consists of a nonvarying, unmodified peptide may be used in 
conjunction with peptide intensity profiling to measure 
changes in histone modifications. Advances in the through-
put of MS-based quantitation assays have increased the ca-
pacity for inhibitor screening in these sensitive and selective 
assays [34]. For example, inhibition of the LSD1 histone 
demethylase has been measured using an eight-way parallel, 
staggered flow injection MS from samples in 384-well plate 
format [35]. Other quantitative methods for measuring his-
tone modifying enzymes utilize various labeling techniques, 
including stable isotope labeling with amino acids in cell 
culture (SILAC) [36], enzymatic incorporation of 
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iTRAQ [38], and chemical tagging of reactive side chains or 
groups with stable isotopes [39]. Stable isotopes may also be 
incorporated into methylated histone residues using [
13CD3]-
labeled SAM in place of the SAM methyl donor [40]. 
Binding Assays 
  Given the low turnover of many histone methyltrans-
ferases, assays that measure displacement of SAM or a pep-
tide substrate may be used to further characterize inhibitors 
or to select potential inhibitors. Fluorescence polarization 
(FP) assays measure changes in fluorescence anisotropy in 
the presence of compounds that displace fluorescently-
labeled cognate peptides from the methyltransferase active 
site. Exploration of the SAR around the G9a inhibitor BIX-
01294 was aided by measuring displacement of a fluo-
rescein-labeled histone H3 peptide upon compound binding 
[16]. A similar FP assay was developed to measure binding 
of histone H4 peptides to PRMT1 [41], and was used for the 
mechanistic analysis and comparison of binding affinities for 
published PRMT1 inhibitors (Table 1) [42]. FP assays, how-
ever, require large amounts of enzyme and may not be ap-
propriate for large-scale discovery of peptide-competitive 
inhibitors. 
Cell-Based Methyltransferase Assays 
  The options for cell-based assays to measure changes in 
posttranslational modifications of histone tails are limited 
and primarily semi-quantitative. The multiplicity of methyl-
transferases and a lack of characterization of their substrates 
make it difficult to assign activity to a particular enzyme. 
Transcriptional changes of genes known to be affected by 
histone methylation at a particular site are frequently used as 
surrogate markers of methyltransferase activity in cells [14]. 
ChIP at methyltransferase target genes may also be used to 
measure methylation changes at promoter-proximal sites. 
Measurements compared before and after knockdown of the 
methyltransferase by genetic or RNAi-based methods assist 
in validation of the inhibitor’s target. 
  Cell-based assays to measure changes in a particular epi-
genetic mark include fluorescence immunostaining with spe-
cific antibodies in live cells [43]. A similar technique is 
standard ELISA with fixed, permeabilized cells using a pri-
mary antibody directed against a specific PTM and a euro-
pium-labeled secondary antibody for TRF detection [14]. As 
discussed above, quantitation of methylation at a specific site 
is complicated by the availability of specific antibodies.  
HISTONE DEMETHYLASES 
  The JmjC domain demethylases utilize non-heme iron 
(II) in a 2-oxoglutarate (2-OG)–dependent oxygenation 
mechanism to demethylate lysine residues of histone tails 
[29]. Their aberrant activities are associated with cancer, 
inflammation, and X-linked mental retardation [44]. Re-
ported inhibitors of the JmjC demethylases include 2,4-
pyridinedicarboxylic acid (PDCA) and hydroxamic acid de-
rivatives, small compounds of micromolar potency that are 
competitive with 2-OG (Table 1) [33]. The coupling enzyme 
formaldehyde dehydrogenase (FDH) has been used to oxi-
dize the demethylase product formaldehyde with concomi-
tant reduction of its NAD
+ cofactor to monitor the change in 
UV absorbance or fluorescence of NADH (Fig. 2B), thus 
producing a convenient real time kinetic assay for JmjC ac-
tivity [45, 46]. AlphaScreen has also been used to measure 
JMJD2E H3K9me3 demethylase activity in vitro. Using a 
panel of 2,4-PDCA analogs, the AlphaScreen assay yielded 
similar IC50 values for JMJD2E inhibition compared to those 
obtained with the FDH-coupled assay [19]. 
  The continuous and homogenous nature of the FDH-
coupled assay allowed its straightforward miniaturization to 
1,536-well plate format [45] and its subsequent use in a 
high-throughput screen of 236,000 compounds for inhibitors 
of the JMJD2E enzyme using an H3K9me3 peptide substrate 
[43]. Of the chemical scaffolds designated as active in the 
screen, optimization of the 8-hyroxyquinolines was per-
formed to generate a 5-carboxy-8HQ cell-permeable com-
pound with 200 nM potency in the enzymatic assay [43]. 
Compared to 2,4-PDCA, the 5-carboxy-8HQ was more se-
lective for JMJD2 enzymes than the 2-OG–dependent hy-
poxia inducible factor prolyl hydroxylases PHD2 and FIH. 
The crystal structure of this compound with the homologous 
JMJD2A protein indicates that 5-carboxy-8HQ disrupts the 
binding of the active site Fe(II).  
  A second family of histone demethylases is the lysine 
specific demethylase (LSD) family, comprised of LSD1 and 
LSD2. These are flavin adenine dinucleotide (FAD)-
dependent amine oxidases that demethylate di- or mono-
methylated H3K4 [47]. The rapid turnover of LSD enzymes 
compared to JMJ enzymes enables easier detection of de-
methylase activity. While LSD enzymes generate formalde-
hyde and may be coupled to FDH, as outlined above, more 
robust assays exist that measure the hydrogen peroxide 
product (Fig. 2B). Horseradish peroxidase (HRP)-coupled 
assays use H2O2 to oxidize a number of HRP substrates in-
cluding 4-aminoantipyrine, AmplexRed (10-acetyl-3,7-
dihydroxyphenoxazine), and luminol for detection using 
absorbance, fluorescence, or chemiluminescence, respec-
tively. 
  Of the reported LSD inhibitors, the majority are mono-
amine oxidase (MAO) inhibitors used in the clinic for anti-
depressant therapy, including pargyline and tranylcypromine 
[48, 49]. These are mechanism-based inhibitors that form 
covalent adducts with the FAD cofactor of LSD1/2 [50, 51]. 
Libraries constructed around these MAO inhibitor scaffolds 
have improved inhibitor potency and selectivity for LSD 
over MAO enzymes [51, 52]. Biguanide and bisguanidine 
polyamine analogues have also been described as LSD1 in-
hibitors and result in reexpression of aberrantly silenced tu-
mor suppressor genes in a human colon cancer cell line [53, 
54]. 
HISTONE CODE READER DOMAINS 
  Protein domains that bind to and recognize posttransla-
tional modifications of histones are referred to as readers of 
the histone code. These domains include the Royal family of 
proteins (chromo-, tudor-, malignant brain tumor-domains, 
others) that recognize PTMs of Lys residues and bromodo-
mains that recognize acetylated Lys [1]. Histone code read-
ers function as adaptors to recruit proteins for further modi-
fication of chromatin structure [2]. In addition to recruitment 
of histone-modifying enzymes, domains that bind specific 
epigenetic marks link histone modification to changes in 
DNA methylation [55]. The important role of these recogni-
tion motifs and their increasing association with disease Methods for Activity Analysis of the Proteins  Current Chemical Genomics, 2011, Volume 5    101 
make compounds that disrupt these protein-protein interac-
tions a novel strategy for targeting epigenetic diseases. 
  The multiplicity of histone code readers suggests diver-
sity in substrate specificity and, indeed, the interactions of 
these protein domains with the large spectrum of histone tail 
PTMs demonstrate a high level of specificity [56]. Crystal 
structures of bromodomains, a recognition domain family 
comprised of at least 57 members, indicate diversity in loop 
regions that dictate substrate specificity despite a conserved 
binding channel [57]. Thus, characterization of disease-
associated epigenetic marks and reader domain specificity is 
crucial in targeting these binding domains. Peptide arrays 
coupled with mass spectrometry are used to bait, capture, 
and identify chromatin-associated domain binding partners 
[58]. Combining this technique with SILAC to expose 
“heavy” cell extracts to post-translationally modified peptide 
bait and “light” cell extracts to unmodified peptide, specific 
binders are distinguished from background binders [36]. 
Characterization of transcriptional target genes may be 
achieved with ChIP-Seq and MS-based sequencing, where 
the histone marks bound by these reader domains should 
overlap with the target gene mapping [59]. 
  Two small molecule compounds that disrupt binding of a 
BRD4 bromodomain to acetylated histones were recently 
published in parallel, providing an excellent proof of concept 
for targeting bromodomains [57, 60]. The very similar tria-
zole-diazepine-fused ring compounds, (+)-JQ1 and I-BET, 
bind stereoselectively to the bromodomain in the acetyl-
lysine binding channel with equilibrium affinities in the 
range of 50 – 100 nM. Filippakopoulos et al. demonstrated 
(+)-JQ1-dependent cellular displacement of BRD4 from 
chromatin and antitumor activity in a mouse xenograft model 
of midline carcinoma [57]. Nicodeme et al. investigated the 
immunomodulatory effects of I-BET and found that it inhib-
ited transcription of inflammatory genes in activated macro-
phages and attenuated the death of mice induced by septic 
shock [60]. Despite the remarkable success in developing 
these small molecule inhibitors of a bromodomain protein-
protein interaction, very little is known about the chemical 
space surrounding other histone code readers, particularly 
regarding methyllysine or methylarginine marks, and high-
throughput assays are needed to identify novel chemical 
scaffolds. 
  Several approaches have been taken to identify small 
molecule disruptors of histone code readers. Fluorescence 
polarization has been used to measure binding affinities of 
histone code readers to fluorescein-labeled peptides (Fig. 
3A) [58, 61, 62]. However, these low affinity micromolar 
interactions make an FP assay format unsuitable for high-
throughput identification of small molecule inhibitors of 
peptide-protein binding. An AlphaScreen assay was devel-
oped using biotinylated histone peptides synthesized with an 
epigenetic mark of interest incorporated to quantify binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Histone demethylase assay formats. (A) Quantitative mass spectrometry measures demethylation of histone peptide substrates by 
identification and relative quantitation of peptides by MS/MS. Here, LSD1 demethylates dimethyl-H3K9 to consecutively generate mono-
methylated and unmodified H3K9 peptides. (B) Activity of JmjC lysine demethylases may be measured by coupling formaldehyde produc-
tion to NAD
+ reduction using the coupling enzyme FDH and monitoring NADH formation. (C) Lysine demethylation catalyzed by LSD1 
can be measured using the coupling enzymes HRP or FDH to quantitate hydrogen peroxide or formaldehyde products, respectively. FDH-
coupled formaldehyde detection is also applicable to the testing of 2-OG–dependent JmjC-domain histone demethylases. 
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to an epitope-tagged reader domain protein (Fig. 3B) [63, 
64]. This assay format allows facile miniaturization to 1,536-
well plate density and is modular in nature with simple sub-
stitution of the reader domain or peptide modification of 
interest. For example, an AlphaScreen assay measuring bind-
ing of the MBT domain protein L3MBTL1 to a monomethy-
lated histone peptide was successfully used to assess inhibi-
tor potency of virtual screening hits identified through phar-
macophore modeling and a methyllysine similarity search 
[65]. A similar approach to measuring these peptide/protein 
interactions may be taken using a TR-FRET readout, for 
example using europium-labeled streptavidin and an accep-
tor fluorophore-conjugated antibody raised against the epi-
tope tag of a reader domain fusion protein (Fig. 3C) [60].  
  Variations of FRET assays have been used in a cell-based 
context to measure bromodomain binding to acetylated his-
tone tails [66, 67]. Fluorescence recovery after photobleach-
ing (FRAP) assays in living cells have also been used to 
show binding of chromatin-associated domains to epigenetic 
marks and a decreased BRD4/chromatin association in the 
presence of (+)-JQ1 [57]. While being effective tools for 
demonstrating a compound’s on-target mode of action, these 
cellular assays to measure binding of epigenetic readers to 
chromatin are lacking in the throughput and quantitative na-
ture necessary for identification of novel small molecules to 
target these protein-protein interactions.  
SUMMARY 
  We have described a number of methods to measure his-
tone methyltransferase and demethylase activity, as well as 
techniques to quantify binding of chromatin-associated do-
mains to post-translationally modified peptides. While 
radioactivity-based assays remain the gold standard for 
evaluating histone-modifying enzymes, a number of robust 
and sensitive assays have been developed to address the 
large number of recently-identified histone methyltrans-
ferases and demethylases. Despite intense efforts to identify 
small molecule modulators of these enzymes, few inhibitors 
have been described. Of these, the majority are non-specific 
SAM competitors or metal ion chelators of methyltransferase 
or demethylase enzymes, respectively. The need exists for 
identification of novel scaffolds as a starting point for drug 
discovery related to epigenetic therapeutic targets. Robust 
high-throughput assays are necessary for screening large 
compound collections to enable detection of these chemical 
chemotypes and their downstream cellular effects. Continued 
improvements in assay technologies and novel methodolo-
gies will enable understanding of the biological role of his-
tone methylation and our ability to mediate the epigenetic 
changes that affect human disease.  
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Fig. (3). Assays to measure binding of histone peptides to histone code reader domains. (A) Histone peptides tagged with a fluorescent 
molecule rotate freely in solution so that incident light is rapidly depolarized. Binding of chromatin-associated domains to specific posttrans-
lational modifications of histone peptides decreases this rotational diffusion and the depolarization of light. (B) AlphaScreen assays measure 
peptide-protein binding of biotinylated- and methylated-histone peptides to His6-tagged chromatin-associated domains, where binding brings 
into close proximity streptavidin-coated donor beads and anti-His6 antibody-conjugated acceptor beads. Laser excitation of donor beads re-
leases singlet oxygen species that excite acceptor beads to generate a chemiluminescent signal. (C) TR-FRET assays measure biotinylated- 
and methylated-peptide binding to His6-protein domains using donor and acceptor dyes in close proximity where the emission spectrum of 
the donor fluorophore overlaps the absorption spectrum of the acceptor molecule. Here, Eu
3+-labeled streptavidin excites anti-His6 antibody 
conjugated with an acceptor dye when the peptide is bound to the reader domain protein.  
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ABBREVIATIONS 
ADA =  adenosine  deaminase 
ChIP =  chromatin  immunoprecipitation 
DELFIA =  dissociation-enhanced lanthanide fluorescent 
immunoassay 
DTNB =  5,5’-dithiobis-2-nitrobenzoic  acid 
ELISA =  enzyme-linked  immunosorbent  assay 
FDH =  formaldehyde  dehydrogenase 
FP =  fluorescence  polarization 
FRAP  =  fluorescence recovery after photobleaching 
FRET  =  fluorescence resonance energy transfer 
HAT =  histone  acetyltransferase 
Hcy =  homocysteine 
HDAC =  histone  deacetylase 
HDM =  histone  demethylase 
HMT =  histone  methyltransferase 
HRP =  horseradish  peroxidase 
HTS =  high-throughput  screening 
LuxS =  S-ribosyl-homocysteinase 
MCE =  microfluidic  capillary  electrophoresis 
MS =  mass  spectrometry 
2-OG =  2-oxoglutarate 
PTM =  posttranslational  modification 
SAH =  S-adenosyl-homocycteine 
SAHH =  SAH-hydrolase 
SAHN =  SAH-nucleosidase 
SAM =  S-adenosyl-methionine 
SPA  =  scintillation proximity assay 
TNB =  5-thio-2-nitrobenzoic  acid 
TRF =  time-resolved  fluorescence 
TR-FRET =  time-resolved FRET 
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